• Company
• Avastin biosimilar "Onbevezy" can be prescribed in earnest
• by Eo, Yun-Ho Jan 21, 2022 05:56am

• Policy
• Alvogen targets the Korean market with a Spanish biosimilar
• by Lee, Tak-Sun Jan 21, 2022 05:56am

• Policy
• Pt management is required to provide high priced 1 shot tx
• by Lee, Hye-Kyung Jan 21, 2022 05:56am

• Company
• CKD Bio & Cutia Therapeutics signed a supply contract
• by Chon, Seung-Hyun Jan 21, 2022 05:55am

• Company
• 60 billion won worth of neutropenia market fluctuates
• by Kim, Jin-Gu Jan 20, 2022 05:55am

• Company
• Second new migraine drug ‘Ajovy’ aims at reimbursement
• by Eo, Yun-Ho Jan 20, 2022 05:55am

• Policy
• Dong-A ST enters Phase III trial for its new OAB treatment
• by Lee, Tak-Sun Jan 20, 2022 05:55am

• Policy
• SK Bioscience has completed recruiting phase 3 participants
• by Kim, Jung-Ju Jan 20, 2022 05:55am

• Policy
• Additional Paxlovid for 10,000 people will be introduced
• by Kang, Shin-Kook Jan 20, 2022 05:54am

• Company
• PCSK9i Praluent can be prescribed after 5 years of approval
• by Eo, Yun-Ho Jan 19, 2022 06:07am